0 avis
Pathogenic role of acyl coenzyme A binding protein (ACBP) in Cushing’s syndrome
Archive ouverte
Edité par CCSD ; Nature Publishing Group -
International audience. Cushing’s syndrome is caused by an elevation of endogenous orpharmacologically administered glucocorticoids. Acyl coenzyme A bindingprotein (ACBP, encoded by the gene diazepam binding inhibitor, Dbi)stimulates food intake and lipo-anabolic reactions. Here we found thatplasma ACBP/DBI concentrations were elevated in patients and mice withCushing’s syndrome. We used several methods for ACBP/DBI inhibition inmice, namely, (1) induction of ACBP/DBI autoantibodies, (2) injection of aneutralizing monoclonal antibody, (3) body-wide or hepatocyte-specificknockout of the Dbi gene, (4) mutation of the ACBP/DBI receptor Gabrg2and (5) injections of triiodothyronine or (6) the thyroid hormone receptor-βagonist resmetirom to block Dbi transcription. These six approachesabolished manifestations of Cushing’s syndrome such as increased foodintake, weight gain, excessive adiposity, liver d am age, hyp ertr ig lyce-ridaemia and type 2 diabetes. In conclusion, it appears that ACBP/DBIconstitutes an actionable target that is causally involved in the developmentof Cushing’s syndrome.